论文部分内容阅读
目的观察乙肝免疫球蛋白在妊娠晚期注射阻断乙型肝炎宫内感染的临床效果。方法对68例HBsAg(+)孕妇,其中有18例HBeAg(+),自孕28周开始每4周肌内注射乙型肝炎免疫球蛋白(HBIG)200IU,分娩后新生儿采脐血5ml,检测乙肝病毒标记物(HBVM)。结果68例新生儿脐血HBsAg阳性者占10.3%,其中HBsAg、HBeAg双阳性者占5.9%。50例仅HBsAg阳性孕妇所生新生儿脐血HBsAg阳性率为4%(2/50),18例HBsAg、HBeAg双阳性孕妇所生新生儿脐血HB-sAg阳性率为27.8%(5/18),两者比较差异有统计学意义。结论HBsAg(+)孕妇孕晚期注射HBIG,阻断宫内HBV感染的效果显著;HBeAg(+)孕妇宫内感染的危险性较大。
Objective To observe the clinical effect of hepatitis B immunoglobulin injection during the third trimester of pregnancy to block intrauterine infection of hepatitis B virus. Methods 68 cases of HBsAg (+) pregnant women, including 18 cases of HBeAg (+), intramuscularly injected hepatitis B immunoglobulin (HBIG) 200IU every 4 weeks from the 28th week of pregnancy, neonatal cord blood 5ml after delivery, Detection of hepatitis B virus markers (HBVM). Results 68 cases of HBsAg positive neonates accounted for 10.3%, of which HBsAg, HBeAg double positive accounted for 5.9%. The positive rate of HBsAg in neonates born from 50 HBsAg-positive pregnant women was 4% (2/50), and the positive rate of HBsAg in cord blood of 18 neonates with positive HBsAg and HBeAg positive was 27.8% (5/18 ), The difference between the two was statistically significant. Conclusion The HBsAg (+) pregnant women injected with HBIG in the third trimester of pregnancy have a significant effect of blocking intrauterine HBV infection. The risk of intrauterine infection of HBeAg (+) pregnant women is higher.